Atlas Trials

Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Clinical trial NCT04891770 · COMPLETED

Trial details

NCT number
NCT04891770
Sponsor
Gilead Sciences
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Hepatitis B
Start date
2021-08-14
Primary completion
2024-01-23
Enrollment
103

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.